阿仑单抗治疗新型冠状病毒肺炎大流行期间的多发性硬化症：尽管免疫抑制严重，但感染轻微且无并发症。 - Suppr

Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.

作者信息

Carandini Tiziana, Pietroboni Anna Margherita, Sacchi Luca, De Riz Milena Alessandra, Pozzato Mattia, Arighi Andrea, Fumagalli Giorgio Giulio, Martinelli Boneschi Filippo, Galimberti Daniela, Scarpini Elio

机构信息

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

University of Milan, Milan, Italy.

出版信息

Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.

DOI:10.1177/1352458520926459

PMID:32463329

Abstract

摘要

相似文献

Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.阿仑单抗治疗新型冠状病毒肺炎大流行期间的多发性硬化症：尽管免疫抑制严重，但感染轻微且无并发症。

Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.

COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作，该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。

Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.

COVID-19 in MS: Initial observations from the Pacific Northwest.多发性硬化症中的新冠病毒病：来自美国太平洋西北地区的初步观察

Neurol Neuroimmunol Neuroinflamm. 2020 May 26;7(5). doi: 10.1212/NXI.0000000000000783. Print 2020 Sep 3.

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.一名多发性硬化症患者在大流行期间开始使用奥瑞珠单抗治疗，感染新冠病毒后预后良好。

Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.

A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.微妙的平衡：免疫抑制与免疫疗法在多发性硬化合并 COVID-19 患者中的应用。

Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.COVID-19 与多发性硬化症：两例阿仑单抗治疗病例描述。

Mult Scler Relat Disord. 2020 Oct;45:102402. doi: 10.1016/j.msard.2020.102402. Epub 2020 Jul 17.

Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.阿仑单抗治疗复发型多发性硬化症后发生的急性呼吸窘迫综合征

Mult Scler Relat Disord. 2017 May;14:1-3. doi: 10.1016/j.msard.2017.03.001. Epub 2017 Mar 12.

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. cladribine 治疗多发性硬化症的轻度或无 COVID-19 症状：两例病例及对临床实践的影响。

Mult Scler Relat Disord. 2020 Oct;45:102452. doi: 10.1016/j.msard.2020.102452. Epub 2020 Aug 16.

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。

Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。

Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.

引用本文的文献

A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic.多发性硬化症患者感染 COVID-19 一年：大流行前后抑郁、睡眠质量和生活质量的检查。

Mult Scler Relat Disord. 2022 Jan;57:103370. doi: 10.1016/j.msard.2021.103370. Epub 2021 Nov 10.

The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders.DAMP 介导体液炎症在重症 COVID-19 及相关疾病中的作用。

Biochem Pharmacol. 2022 Jan;195:114847. doi: 10.1016/j.bcp.2021.114847. Epub 2021 Nov 18.

The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.控制多发性硬化症的免疫治疗策略：COVID-19 大流行期间的考虑因素。

Biomolecules. 2021 Sep 17;11(9):1372. doi: 10.3390/biom11091372.

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述

Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.

Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.用于治疗多发性硬化症的抗CD52疗法：新冠疫情时代的最新进展

Immunotargets Ther. 2021 Jul 7;10:237-246. doi: 10.2147/ITT.S240890. eCollection 2021.

SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.西班牙神经病学学会登记处：多发性硬化症中的 SARS-CoV-2 感染结果。

Neurol Neuroimmunol Neuroinflamm. 2021 Jun 24;8(5). doi: 10.1212/NXI.0000000000001024. Print 2021 Jul.

Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.COVID-19 大流行期间治疗多发性硬化症的药物：批判性观点。

Curr Neuropharmacol. 2022;20(1):107-125. doi: 10.2174/1570159X19666210330094017.

[Neuroimmunology of COVID-19].[新型冠状病毒肺炎的神经免疫学]

Nervenarzt. 2021 Jun;92(6):521-530. doi: 10.1007/s00115-021-01077-1. Epub 2021 Mar 2.

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.COVID-19 与中枢神经系统脱髓鞘疾病患者的疾病修正治疗：系统评价。

Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.

Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?多发性硬化症与2019冠状病毒病：大流行期间治疗方案可能如何变化？

J Med Virol. 2021 Apr;93(4):1847-1849. doi: 10.1002/jmv.26796. Epub 2021 Jan 22.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献